Literature DB >> 16469871

Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation.

Vincent Holl1, Maryse Peressin, Sylvie Schmidt, Thomas Decoville, Susan Zolla-Pazner, Anne-Marie Aubertin, Christiane Moog.   

Abstract

During mucosal HIV transmission, immature dendritic cells (DCs) present in the mucosa are among the first cellular targets of the virus. Previous studies have analyzed the inhibition of HIV-1 transfer from human mature DCs to T lymphocytes by neutralizing IgG, but so far no in vitro data regarding the capacity of antibodies to inhibit HIV-1 infection of immature DCs have been reported. Here, we found an increased HIV-inhibitory activity of monoclonal IgG and purified polyclonal IgG when immature monocyte-derived dendritic cells (iMDDCs) were used as target cells instead of autologous blood lymphocytes. We showed that FcgammaRII is involved in the mechanism for inhibiting HIV-1 infection of iMDDCs by IgG, whereas no induction of maturation was detected at concentrations of IgG that result in a 90% reduction of HIV replication. After induction of FcgammaRI expression on iMDDCs by IFN-gamma, an augmentation of the HIV-inhibitory activity of IgG, related to the expression of FcgammaRI, was observed. Taken together, our results demonstrate the participation of FcgammaRs in HIV-1 inhibition by IgG when iMDDCs are the targets. We propose that IgG is able to efficiently inhibit HIV-1 replication in iMDDCs and should be one of the components to be induced by vaccination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469871      PMCID: PMC1895798          DOI: 10.1182/blood-2005-08-3490

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  61 in total

1.  DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells.

Authors:  T B Geijtenbeek; D S Kwon; R Torensma; S J van Vliet; G C van Duijnhoven; J Middel; I L Cornelissen; H S Nottet; V N KewalRamani; D R Littman; C G Figdor; Y van Kooyk
Journal:  Cell       Date:  2000-03-03       Impact factor: 41.582

2.  Monocyte-derived dendritic cells as a model for the study of HIV-1 infection: productive infection and phenotypic changes during culture in human serum.

Authors:  D F Mallon; A Buck; J C Reece; S M Crowe; P U Cameron
Journal:  Immunol Cell Biol       Date:  1999-10       Impact factor: 5.126

3.  Immune complexes as therapy for autoimmunity.

Authors:  Raphael Clynes
Journal:  J Clin Invest       Date:  2005-01       Impact factor: 14.808

4.  The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication.

Authors:  Y Bakri; C Schiffer; V Zennou; P Charneau; E Kahn; A Benjouad; J C Gluckman; B Canque
Journal:  J Immunol       Date:  2001-03-15       Impact factor: 5.422

Review 5.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

6.  Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.

Authors:  R Burrer; D Salmon-Ceron; S Richert; G Pancino; G Spiridon; S Haessig; V Roques; F Barre-Sinoussi; A M Aubertin; C Moog
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

7.  Human immunodeficiency virus type 1 gp120 induces abnormal maturation and functional alterations of dendritic cells: a novel mechanism for AIDS pathogenesis.

Authors:  Laura Fantuzzi; Cristina Purificato; Karim Donato; Filippo Belardelli; Sandra Gessani
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Polyclonal immunoglobulin G from patients neutralizes human immunodeficiency virus type 1 primary isolates by binding free virions, but without interfering with an initial CD4-independent attachment of the virus to primary blood mononuclear cells.

Authors:  Renaud Burrer; Sandrine Haessig-Einius; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells.

Authors:  Jean-François Fonteneau; Marie Larsson; Anne-Sophie Beignon; Kelli McKenna; Ida Dasilva; Ali Amara; Yong-Jun Liu; Jeffrey D Lifson; Dan R Littman; Nina Bhardwaj
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  HIV-1-infected monocyte-derived dendritic cells do not undergo maturation but can elicit IL-10 production and T cell regulation.

Authors:  Angela Granelli-Piperno; Angelika Golebiowska; Christine Trumpfheller; Frederick P Siegal; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-05       Impact factor: 11.205

View more
  36 in total

1.  HIV-1 N-glycan composition governs a balance between dendritic cell-mediated viral transmission and antigen presentation.

Authors:  Thijs van Montfort; Dirk Eggink; Maikel Boot; Michael Tuen; Catarina E Hioe; Ben Berkhout; Rogier W Sanders
Journal:  J Immunol       Date:  2011-09-28       Impact factor: 5.422

2.  Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells.

Authors:  Vincent Holl; Maryse Peressin; Thomas Decoville; Sylvie Schmidt; Susan Zolla-Pazner; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

3.  A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Authors:  Thorsten Demberg; Ruth H Florese; Megan J Heath; Kay Larsen; Irene Kalisz; V S Kalyanaraman; Eun Mi Lee; Ranajit Pal; David Venzon; Richard Grant; L Jean Patterson; Birgit Korioth-Schmitz; Adam Buzby; Dilani Dombagoda; David C Montefiori; Norman L Letvin; Aurelio Cafaro; Barbara Ensoli; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

4.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

5.  Stimulation of HIV-1 replication in immature dendritic cells in contact with primary CD4 T or B lymphocytes.

Authors:  Vincent Holl; Ke Xu; Maryse Peressin; Alexandre Lederle; Marina Elizabeth Biedma; Maryse Delaporte; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Anne-Marie Aubertin; Christiane Moog
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

6.  A new lease on life for an HIV-neutralizing antibody class and vaccine target.

Authors:  Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2021-02-16       Impact factor: 11.205

7.  Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b.

Authors:  Margaret E Ackerman; Anne-Sophie Dugast; Elizabeth G McAndrew; Stephen Tsoukas; Anna F Licht; Darrell J Irvine; Galit Alter
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

8.  Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.

Authors:  Lautaro G Perez; Susan Zolla-Pazner; David C Montefiori
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

9.  Dendritic cell-lymphocyte cross talk downregulates host restriction factor SAMHD1 and stimulates HIV-1 replication in dendritic cells.

Authors:  Bin Su; Marina Elizabeth Biedma; Alexandre Lederle; Maryse Peressin; Mélanie Lambotin; Alizé Proust; Thomas Decoville; Sylvie Schmidt; Géraldine Laumond; Christiane Moog
Journal:  J Virol       Date:  2014-02-26       Impact factor: 5.103

Review 10.  Antibodies against viruses: passive and active immunization.

Authors:  Mansun Law; Lars Hangartner
Journal:  Curr Opin Immunol       Date:  2008-07-01       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.